The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

A new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved the treatment's effectiveness in patients with metastatic gastrointestinal ...

A new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved ...

As of December 31, 2024, Fortress' consolidated cash and cash equivalents totaled $57.3 million, compared to $58.9 million as ...

COPENHAGEN, Denmark I March 31, 2025 I Genmab A/S (Nasdaq: GMAB)announced today that the European Commission (EC) has granted marketing authorization for ...

Discover why Immutep's Eftilagimod Alpha shows promise in NSCLC and HNSCC trials, but cautious investment is advised. Explore more details here.

SAN FRANCISCO and SUZHOU, China, March 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutic ...

EMA committee recommends approval of Bristol Myers Squibb’s subcutaneous formulation of Opdivo across multiple solid tumour indications: Princeton, New Jersey Monday, March 31, ...

Key Highlights: <li /> Global first immuno + anti-vascular bispecific antibody approved: ivonescimab for EGFR-TKI resistant nsq-NSCLC.

Discover a recent study that has evaluated the risk of poor prognosis and recurrence, alongside risk factor presence in ...

Q4 2024 Earnings Call Transcript March 27, 2025 PDS Biotechnology Corporation beats earnings expectations. Reported EPS is ...